Sanofi spins out its consumer healthcare business | Business ...

French pharma giant Sanofi is selling off its consumer healthcare business Opella. US-based investment firm Clayton, Dubilier & Rice (CD&R) is to take a controlling 50% stake, while ...

CouponFollow Extension

50%
OFF

Sanofi Spins Out Its Consumer Healthcare Business | Business ...

2 weeks from now

French pharma giant Sanofi is selling off its consumer healthcare business Opella. US-based investment firm Clayton, Dubilier & Rice (CD&R) is to take a controlling 50% stake, while ...

chemistryworld.com

$53.83
OFF

Sanofi Cancels Consumer Healthcare Business Spin-Off

2 weeks from now

Forbes • 10/30/24. Sanofi Cancels Consumer Healthcare Business Spin-Off. On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN …

public.com

16%
OFF

Sanofi Stock Dips On Plans To Spin Off Consumer Healthcare Unit

2 weeks from now

Oct 27, 2023 · Sanofi (NASDAQ:SNY) shares plunged 16% premarket on Friday after the drugmaker reported its third quarter results and laid out plans to spin off its consumer …

seekingalpha.com

€15
OFF

CD&R Beats Rivals In Pursuit Of €15.5bn Sanofi Consumer Health Unit

2 weeks from now

Oct 11, 2024 · In 2021, GSK and Pfizer listed their joint-venture consumer healthcare business Haleon in London, while Johnson & Johnson of the US separated off its consumer company …

ft.com

$5
OFF

Sanofi's Planned Consumer Health Spinoff Picks Up Interest From ...

2 weeks from now

Feb 21, 2024 · Sanofi’s consumer healthcare unit pulled down €5.18 billion ($5.6 billion) during 2023. The spinoff could take flight during this year’s fourth quarter “at the earliest,” according to ...

fiercepharma.com

€20
OFF

Sanofi Pushes Ahead With €20bn Consumer Healthcare Spin-off

2 weeks from now

Jun 2, 2024 · In 2022, GSK spun off its consumer healthcare business Haleon, a joint venture with Pfizer, while Johnson & Johnson also listed its consumer business Kenvue in 2023. …

ft.com

$3
OFF

Sanofi Kicks Off Share Buyback Plan With $3bn L’Oréal Stake Purchase

2 weeks from now

4 days ago · Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L’Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025.. L’Oréal was …

pharmaceutical-technology.com

17%
OFF

L’Oreal To Sell $3.1 Billion Stake In Sanofi Back To Pharma Group

2 weeks from now

L’Oreal OR2.17%increase; green up pointing triangle will sell part of its stake in Sanofi SAN 0.12%increase; green up pointing triangle back to the French pharmaceutical company for 3 …

wsj.com

FAQs about Sanofi spins out its consumer healthcare business | Business ... Coupon?

Will Sanofi spin off its consumer health business?

Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts on its prescription drugs business. ...

Why did Sanofi cancel a spin-off?

Sanofi’s decision to cancel the spin-off of its consumer healthcare business and go ahead with a sell a 50% stake to CD&R reflects a strategic shift aimed at focusing more on its core pharmaceutical and biotech operations. ...

Why did Sanofi sell its Biopharma business?

The sale comes as Sanofi aims to accelerate its R&D investments and increase focus on its biopharma business. The move reflects a wider trend across the industry, with several major pharma companies splitting off their consumer health divisions in recent years. ...

Is Sanofi selling Opella?

By Jamie Durrani 30 October 2024 French pharma giant Sanofi is selling off its consumer healthcare business Opella. US-based investment firm Clayton, Dubilier & Rice (CD&R) is to take a controlling 50% stake, while Sanofi will retain a 48% interest. ...

Will Sanofi keep a stake in a consumer health unit?

Spinning off consumer health units has become a popular trend among large pharma companies—though Sanofi CEO Paul Hudson said Monday that the company is interested in keeping a stake in its unit once the separation is done, according to Reuters. ...

Will Sanofi become a listed company in France?

In its original announcement, Sanofi noted that the “most likely path” forward for the business would be a capital markets transaction to create a listed entity in France. Sanofi’s consumer health business pulled in 5.2 billion euros ($5.6 billion) in 2023, representing 11% of the French pharma’s total revenue. ...